<VariationArchive VariationID="1351706" VariationName="NC_000016.9:g.(?_2106344)_(2107114_?)del" VariationType="Deletion" Accession="VCV001351706" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1486094" VariationID="1351706">
      <GeneList>
        <Gene Symbol="TSC2" FullName="TSC complex subunit 2" GeneID="7249" HGNC_ID="HGNC:12363" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="2047985" stop="2089491" display_start="2047985" display_stop="2089491" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="2097989" stop="2138712" display_start="2097989" display_stop="2138712" Strand="+" />
          </Location>
          <OMIM>191092</OMIM>
          <Haploinsufficiency last_evaluated="2020-06-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TSC2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-06-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TSC2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000016.9:g.(?_2106344)_(2107114_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" innerStart="2106344" innerStop="2107114" display_start="2106344" display_stop="2107114" variantLength="771" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.(?_2106344)_(2107114_?)del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.(?_2106344)_(2107114_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000016.9:g.(?_2106344)_(2107114_?)del AND Tuberous sclerosis 2" Accession="RCV002044931" Version="4">
        <ClassifiedConditionList TraitSetID="3366">
          <ClassifiedCondition DB="MedGen" ID="C1860707">Tuberous sclerosis 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-11-24" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-11-24" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10205261</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16199547</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17304050</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21309039</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32211034</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3366" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6897" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Tuberous sclerosis 2</ElementValue>
                <XRef ID="Tuberous+sclerosis%2C+type+2/7257" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013199" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">TSC2</ElementValue>
                <XRef Type="MIM" ID="613254" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15640" />
                <XRef ID="15640" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Tuberous sclerosis complex (TSC) involves abnormalities of the skin (hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques, ungual fibromas); brain (subependymal nodules, cortical tubers, and subependymal giant cell astrocytomas [SEGAs], seizures, intellectual disability / developmental delay, psychiatric illness); kidney (angiomyolipomas, cysts, renal cell carcinomas); heart (rhabdomyomas, arrhythmias); and lungs (lymphangioleiomyomatosis [LAM], multifocal micronodular pneumonocyte hyperplasia). Central nervous system tumors are the leading cause of morbidity and mortality; renal disease is the second leading cause of early death.</Attribute>
                <XRef ID="NBK1220" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5381" />
                <XRef ID="5381" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301399</ID>
                <ID Source="BookShelf">NBK1220</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2007">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_TuberousSclerosis.pdf</URL>
                <CitationText>Orphanet, Tuberous sclerosis, 2007</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="805" DB="Orphanet" />
              <XRef ID="C1860707" DB="MedGen" />
              <XRef ID="MONDO:0013199" DB="MONDO" />
              <XRef Type="MIM" ID="613254" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4125826" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="NM_000548.3_16_Partial deletion (exons 8-9)_2106343_2107114|MedGen:C1860707" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002113032" DateUpdated="2024-06-09" DateCreated="2022-03-28" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-11-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16199547</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10205261</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17304050</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32211034</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21309039</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has been observed in individual(s) with tuberous sclerosis complex (Invitae). This variant results in the deletion of exon 8 and part of exon 9 (c.648+100_784del) of the TSC2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TSC2 are known to be pathogenic (PMID: 10205261, 17304050). This variant disrupts the p.Leu219 amino acid residue in TSC2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 32211034, 21309039). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TSC2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.(?_2106344)_(2107114_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1860707" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4125826" TraitType="Disease" MappingType="XRef" MappingValue="C1860707" MappingRef="MedGen">
        <MedGen CUI="C1860707" Name="Tuberous sclerosis 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

